Clinicians must interpret existing knowledge and new evidence as it arises, from well designed, conducted and reported clinical trials to guarantee the best quality of patient care. Clinical evidence is typically collected in an incremental and iterative process where new information is added to existing knowledge. However, the reporting of results from many trials often leads to uncertainty among clinicians on how to interpret a trial's outcomes with the translation of research into practice at times also challenged by prior established practices and beliefs. Traditionally, clinical trials are reported using P values and confidence intervals (CI) relevant to the study hypothesis (most commonly the null hypothesis of zero difference) and effect estimate (often the odds or risk ratio). This approach to inference of trial results is referred to as frequentist and uses data from a single trial in isolation and assigns the probability that the observed outcome has arisen by chance from a hypothetical number of repetitions of the trial (but not that the findings are erroneous or that the hypothesis is false). By convention, a threshold probability of P < .05 given the power of the trial is used as a compromise between type-1 (false positive) and type-2 (false negative) errors to reject the assumption of a chance finding. This approach furthermore leads to a dichotomisation of results that are reported as 'significant' or 'non-significant' purely based on frequentist statistical inference with the 'non-significant' result often receiving a connotation of a 'negative' trial or showing an 'absence' of effect. 1,2 It comes as no surprise that the P value has been criticised with calls made for an alternative approach to inference. [3][4][5][6][7] Using a Bayesian approach of inference, new trial results are considered in the context of existing information (please refer to the Appendix S1 for an explanation of Bayes theorem in an